Kriti Agrawal

Kriti Agrawal

Auto-generated profile, based on publicly available information

Kriti Agrawal

Department of Pathology, Yale School of Medicine; Department of Immunobiology, Yale School of Medicine

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2024 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
SASeth A. Ament
Seth A. Ament
RCRianne R. Campbell
Rianne R. Campbell
MLMary Kay Lobo
Mary Kay Lobo
JRJoseph P. Receveur
Joseph P. Receveur
KAKriti Agrawal
Kriti Agrawal
HZHongkui Zeng
Hongkui Zeng
Substance use disorders (SUD) and drug addiction are major threats to public health, impacting not only the millions of individuals struggling with SUD, but also surrounding families and communities. One of the seminal challenges in treating and studying addiction in human populations is the high prevalence of co-morbid conditions, including an increased risk of contracting a human immunodeficiency virus (HIV) infection. Of the ~15 million people who inject drugs globally, 17% are persons with HIV. Conversely, HIV is a risk factor for SUD because chronic pain syndromes, often encountered in persons with HIV, can lead to an increased use of opioid pain medications that in turn can increase the risk for opioid addiction. We hypothesize that SUD and HIV exert shared effects on brain cell types, including adaptations related to neuroplasticity, neurodegeneration, and neuroinflammation. Basic research is needed to refine our understanding of these affected cell types and adaptations. Studying the effects of SUD in the context of HIV at the single-cell level represents a compelling strategy to understand the reciprocal interactions among both conditions, made feasible by the availability of large, extensively-phenotyped human brain tissue collections that have been amassed by the Neuro-HIV research community. In addition, sophisticated animal models that have been developed for both conditions provide a means to precisely evaluate specific exposures and stages of disease. We propose that single-cell genomics is a uniquely powerful technology to characterize the effects of SUD and HIV in the brain, integrating data from human cohorts and animal models. We have formed the Single-Cell Opioid Responses in the Context of HIV (SCORCH) consortium to carry out this strategy.

25 December 2025 in Blood
Verified
Journal Article
Open access
NNNathan M. Newton
Nathan M. Newton
KAKriti Agrawal
Kriti Agrawal
AOAnahi V. Odell
Anahi V. Odell
TTTimothy Tracy
Timothy Tracy
CHCraig Hackett
Craig Hackett
IOIan D. Odell
Ian D. Odell
Immune-driven fibrotic skin diseases, including scleroderma/systemic sclerosis (SSc) and chronic graft-versus-host disease (GVHD), cause skin stiffening that has a major impact on patient quality of life and associated patient mortality. Therapies to improve sclerotic skin resulting from these diseases are largely ineffective. We previously showed that epiregulin (EREG), a dendritic cell type 3–derived epidermal growth factor receptor (EGFR) ligand, is elevated in the skin and lungs of patients with SSc and required for the maintenance of skin fibrosis. Here, we developed a fully human anti-EREG neutralizing antibody that has both high affinity and specificity. We found this therapeutic antibody to be functional and safe in vivo using human EREG knockin mice. To understand the antifibrotic mechanism of targeting EREG, we aligned skin single-cell transcriptomic profiles of SSc, morphea (localized scleroderma), and sclerotic GVHD (SclGVHD) with disease biomarkers. EREG expression in the skin was elevated in all 3 fibrotic diseases and is a driver of tenascin C (TNC) production by myofibroblasts. TNC is a proinflammatory extracellular glycoprotein that functions as an endogenous Toll-like receptor 4 (TLR4) ligand, which induces expression of TLR4 target genes CCL2 and interleukin-6. Examination of skin explants from patients with active SclGVHD treated with anti-EREG therapeutic antibody by spatial transcriptomics demonstrated upregulation of matrix degradation by increased MMP and decreased TIMP1 expression. Protein measurements showed reduced secretion of EREG targets TNC, CCL2, and TIMP1 in all patients and type I collagen and FN1 in three-fourths of patients. Thus, sclerotic skin treated with the anti-EREG therapeutic antibody reduced inflammatory and fibrosis biomarkers associated with EGFR and TLR4 signaling.

26 February 2026 in Research Square
Verified
Preprint
Open access
PDF file
HMHaris Mirza
Haris Mirza
BTBirgit Tschiatschek
Birgit Tschiatschek
MMMiraal Maqsood
Miraal Maqsood
XLXumin Li
Xumin Li
MOMin-Hee Oh
Min-Hee Oh
RFRichard Flavell
Richard Flavell
Crypt fixation is an early and essential event of colorectal cancer initiation 1–6. It is an evolutionary process where precancerous stem cells compete with their healthy neighbors for monoclonal fixation of intestinal crypts 1–6. This competition involves stochastic interaction between three cell populations, oncogene mutant clones, competing wild-type clones and the cells populating their microenvironment. Interactions between competing WT and mutant clones are well studied; however, the impact of the microenvironment cells on crypt fixation, has been challenging to quantify 1–6. This is due to the absence of suitable experimental and theoretical models to study three-way stochastic interactions between competing clones and cells in their microenvironment. To overcome this challenge, we integrated established mosaic clonal selection models1,7,8 and immune depletion models9 with the theoretical framework provided by Stochastic Conveyor Belt model 10,11. Using this approach, we quantified the selective advantage of colonic stem cells with the BRAFV600E mutation, one of the most prevalent human oncogenes. We showed that BRAFV600E confers a selective advantage to colonic stem cells but approximately half of the clones are destined for clonal extinction. We show mechanistically that clonal extinction of these precancerous cells is actively mediated by adaptive immune system. Specific depletion of regulatory T cells or targeted deletion of Major Histocompatibility Complex Class II (MHCII) or interleukin 10 receptor A (IL10RA) on the BRAFV600E mutated clones, prevented their extinction. Overall, these findings reveal a new immune sensing mechanism whereby Tregs recognize and eliminate precancerous stem cells before malignant transformation. Understanding this interplay between microenvironment and stem cell dynamics at tumor initiation will enable the development of immunoprevention strategies against colon cancer initiation, rather than treat existing tumors. *Birgit Tschiatschek & Miraal Maqsood contributed equally.